CD279 Recombinant Protein

Description of CD279 Recombinant Protein

General information on CD279 Recombinant Protein:

CD279 (programmed cell death protein 1; PD-1) is a type I transmembrane protein that belongs to the CD28 / CTLA-4 family of immune receptors, which mediates signals that regulate immune responses. Members of the CD28 / CTLA-4 family have been shown to promote T cell activation (CD28 and ICOS) or deactivate T cell activation (CTLA-4 and PD-1). CD279 is expressed on activated T cells, B cells, bone marrow cells, and some thymocytes. In vitro, CD279 binding can prevent TCR-mediated T cell proliferation and the production of IL-1, IL-4, IL-10, and IFN-γ. Furthermore, the binding of CD279 can also prevent BCR signaling. CD279-deficient mice have defective peripheral tolerance and spontaneously develop autoimmune diseases.

Nivolumab Biosimilar - Anti-PD1 mAb binds to CD279 Recombinant Protein in indirect ELISA Assay

Immobilized CD279 Recombinant Protein (cat. No.PX-P4117) at 0.5µg/mL (100µL/well) can bind to Nivolumab Biosimilar - Anti-PD1 mAb (cat. No.PX-TA1004) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450

Dostarlimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb binds to CD279 Recombinant Protein in indirect ELISA Assay

Immobilized CD279 Recombinant Protein (cat. No.PX-P4117) at 0.5µg/mL (100µL/well) can bind to Dostarlimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb (cat. No.PX-TA1526) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450

Cemiplimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb - Research Grade binds to CD279 Recombinant Protein in ELISA assay

Immobilized CD279 Recombinant Protein (cat. No.PX-P4117) at 0.5µg/mL (100µL/well) can bind Cemiplimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb - Research Grade (cat. No.PX-TA1524) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 905.4M.

Balstilimab Biosimilar - Anti-PDCD1; PD1; CD279 mAb - Research Grade binds to CD279 Recombinant Protein in ELISA assay

Immobilized CD279 Recombinant Protein (cat. No.PX-P4117) at 0.5µg/mL (100µL/well) can bind Balstilimab Biosimilar - Anti-PDCD1; PD1; CD279 mAb - Research Grade (cat. No.PX-TA1558) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 9.940M.

Cetrelimab Biosimilar - Anti-PDCD1; PD1; CD279 mAb - Research Grade binds to CD279 Recombinant Protein in ELISA assay

Immobilized CD279 Recombinant Protein (cat. No.PX-P4117) at 0.5µg/mL (100µL/well) can bind Cetrelimab Biosimilar - Anti-PDCD1; PD1; CD279 mAb - Research Grade (cat. No.PX-TA1513) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 99.31M.

Tislelizumab Biosimilar - Anti-PDCD1; PD1; CD279 mAb - Research Grade binds to CD279 Recombinant Protein in ELISA assay

Immobilized CD279 Recombinant Protein (cat. No.PX-P4117) at 0.5µg/mL (100µL/well) can bind Tislelizumab Biosimilar - Anti-PDCD1; PD1; CD279 mAb - Research Grade (cat. No.PX-TA1479) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 133.8M.

Sintilimab Biosimilar - Anti-PDCD1; PD1; CD279 mAb - Research Grade binds to CD279 Recombinant Protein in ELISA assay

Immobilized CD279 Recombinant Protein (cat. No.PX-P4117) at 0.5µg/mL (100µL/well) can bind Sintilimab Biosimilar - Anti-PDCD1; PD1; CD279 mAb - Research Grade (cat. No.PX-TA1536) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 44.44M.

Toripalimab Biosimilar - Anti-PDCD1; PD1; CD279 mAb - Research Grade binds to CD279 Recombinant Protein in ELISA assay

Immobilized CD279 Recombinant Protein (cat. No.PX-P4117) at 0.5µg/mL (100µL/well) can bind Toripalimab Biosimilar - Anti-PDCD1; PD1; CD279 mAb - Research Grade (cat. No.PX-TA1540) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 46.26M.

Pembrolizumab Biosimilar - Anti-PD1 mAb binds to CD279 Recombinant Protein in indirect ELISA Assay

Immobilized CD279 Recombinant Protein (cat. No.PX-P4117) at 0.5µg/mL (100µL/well) can bind to Pembrolizumab Biosimilar - Anti-PD1 mAb (cat. No.PX-TA1007) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450